Thank you for finding out more about the **PASSAGE Study**
– this leaflet will tell you a bit more about it and what it means to take part.

**What is the PASSAGE Study?**
This is a clinical study of a drug called tezepelumab (TEZSPIRE®) for severe asthma, which is already approved in the US for adults and adolescents aged 12 years and older. The **PASSAGE Study** will investigate how this drug works in people with severe asthma and in under-represented populations, and the information we collect might help others with asthma in the future.

**Who can take part?**
The **PASSAGE Study** is open to adults and adolescents who are aged 12 years and older. People with all kinds of asthma can take part, and we particularly want to hear from people in the 4 groups below:

1. If you identify as Black or African American
2. If you are aged 12–17 years
3. If you have mild-to-moderate COPD
4. If you have a long history of smoking or have smoked a lot (including current and former smokers).

**What is tezepelumab (TEZSPIRE®)?**
Tezepelumab (TEZSPIRE®) has been approved by the US Food and Drug Administration for severe asthma. It will be given as an injection under the skin every 4 weeks. Taking TEZSPIRE® could mean fewer attacks, better breathing, and improved asthma symptom control.

**What else do I need to know?**
You will be in the **PASSAGE Study** for about a year. You will be asked to attend monthly study visits to receive the study drug injections. You will also have lung function tests (measuring how well you can move air in and out of your lungs) and be asked to fill in questionnaires at different times during the study. There are also blood tests during the study.

Your travel expenses will be covered for each study visit.

You cannot take part if you have been taking another asthma biologic (for example, injectable drugs like Dupixent®, Nucala, Fasenra®, Cinqair®, Xolair®) in the last 4 months.

Scan me to learn more!

Please speak to the person who gave you this flyer if you are interested in taking part or call this number:

They can discuss the study requirements with you and answer any questions you might have. If you don’t join the study, you will continue to receive care for your asthma.